Q-omics provides the consensus-scored METTL14 profile across patient tissues and cancer cell-line models. METTL14 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, METTL14 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, METTL14 RNA expression shows 20,983 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where METTL14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL14 survival associations across molecular data types. METTL14 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL14 RNA expression–survival associations across cancer types. High METTL14 expression shows unfavorable associations in MESO, but favorable associations in KIRC, READ, BRCA, ACC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for METTL14 RNA expression.
This table summarizes METTL14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for METTL14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL14 shows lower tumor expression in THCA, LUAD, UCEC and KICH and higher tumor expression in HNSC and LIHC. The THCA box plot shows higher METTL14 RNA expression in normal versus tumor tissue (log2 FC = −0.802, t-test p < 0.001).
This table shows molecular features associated with METTL14 in patient tissues and cancer cell lines. In patient samples, METTL14 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, METTL14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
